Increased Serum Levels of the IL-33 Neutralizing sST2 in Limited Cutaneous Systemic Sclerosis.

about

Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy.An update on biomarker discovery and use in systemic sclerosis.IL-33/ST2 Axis in Organ Fibrosis

P2860

Q38753216-C595CC13-285D-4C0F-80AA-A86322198142 Q39450087-81F37C2F-9780-4B5A-AACF-BC9AAC730260 Q58566658-0B494C4A-6980-4633-AF65-5FE6651FE1DE

P2860

Increased Serum Levels of the IL-33 Neutralizing sST2 in Limited Cutaneous Systemic Sclerosis.

Item

http://www.wikidata.org/entity/Q48168794

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Increased Serum Levels of the ...... Cutaneous Systemic Sclerosis.

@en

Increased Serum Levels of the ...... Cutaneous Systemic Sclerosis.

@nl

type

Item

label

Increased Serum Levels of the ...... Cutaneous Systemic Sclerosis.

@en

Increased Serum Levels of the ...... Cutaneous Systemic Sclerosis.

@nl

prefLabel

Increased Serum Levels of the ...... Cutaneous Systemic Sclerosis.

@en

Increased Serum Levels of the ...... Cutaneous Systemic Sclerosis.

@nl

P1476

Increased Serum Levels of the ...... Cutaneous Systemic Sclerosis.

@en

P2093

A Wagner

http://www.w3.org/2001/XMLSchema#string

J M Pfeilschifter

http://www.w3.org/2001/XMLSchema#string

M Köhm

http://www.w3.org/2001/XMLSchema#string

P2860

The dual function cytokine IL-33 interacts with the transcription factor NF-κB to dampen NF-κB-stimulated gene transcription

Interleukin-33 and the function of innate lymphoid cells

Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin.

Interleukin 33: a switch-hitting cytokine.

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative.

A role for soluble ST2 in vascular remodeling associated with obesity in rats.

Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis.

Microvascular abnormalities in patients with early systemic sclerosis: less severe morphological changes than in patients with definite disease.

Interleukin-33 potentiates bleomycin-induced lung injury.

Diagnosis and classification of systemic sclerosis.

P304

269-274

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/SJI.12317

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Elisabet Svenungsson

Heinfried H. Radeke

Annika Nordin

P577

2015-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

278968901

http://www.w3.org/2001/XMLSchema#string

P698

26095613

http://www.w3.org/2001/XMLSchema#string

Increased Serum Levels of the IL-33 Neutralizing sST2 in Limited Cutaneous Systemic Sclerosis.

about

P2860

P2860

Increased Serum Levels of the IL-33 Neutralizing sST2 in Limited Cutaneous Systemic Sclerosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698